TriSalus Life Sciences (NASDAQ:TLSI) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of TriSalus Life Sciences (NASDAQ:TLSI) from a hold rating to a sell rating in a report issued on Saturday,Wall Street Zen reports.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Wednesday, November 4th. Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Zacks Research upgraded TriSalus Life Sciences to a “hold” rating in a research note on Thursday, September 10th. Stifel Nicolaus set a $12.00 price objective on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Finally, HC Wainwright boosted their target price on TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, September 23rd. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.20.

TriSalus Life Sciences Trading Down 0.9%

Shares of TLSI opened at $3.22 on Friday. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. TriSalus Life Sciences has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The firm’s 50-day simple moving average is $4.25 and its two-hundred day simple moving average is $4.35.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Cura Wealth Advisors LLC purchased a new stake in shares of TriSalus Life Sciences during the second quarter valued at $36,000. Russell Investments Group Ltd. bought a new stake in TriSalus Life Sciences in the 3rd quarter worth about $68,000. Provenance Wealth Advisors LLC purchased a new position in TriSalus Life Sciences in the 3rd quarter worth about $94,000. Renaissance Technologies LLC purchased a new position in TriSalus Life Sciences in the 1st quarter worth about $124,000. Finally, Deutsche Bank AG purchased a new position in TriSalus Life Sciences in the 2nd quarter worth about $221,000. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.